Exposure to PFAS Mixtures Linked to Increased Odds of Type 2 Diabetes
By Elana Gotkine HealthDay Reporter
FRIDAY, July 25, 2025 -- In multiethnic populations, exposure to per- and polyfluoroalkyl substance (PFAS) mixtures may be associated with increased odds of type 2 diabetes (T2D), according to a study published online July 21 in eBioMedicine.
Vishal Midya, Ph.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues examined the associations between exposure to PFAS mixtures with later T2D diagnosis and underlying metabolic dysregulation in a nested case-control study within an electronic health record-linked biobank of >65,000 patients seeking primary care at Mount Sinai Hospital since 2007. A total of 180 incident T2D cases and 180 age-, sex-, and ancestry-matched T2D controls were selected. Seven PFAS and unquantified metabolomic profiles were quantified in prediagnostic plasma collected at baseline (about six years before diagnosis). Weighted Quantile Sum regression was used to assess the PFAS mixture associated with the odds of incident T2D.
The researchers found that the odds of incident T2D were increased in association with each tertile increase in the PFAS mixture (odds ratio, 1.31), with perfluorooctane sulfonate contributing most to this association. The metabolites 5-hydroxytryptophan, glucoheptulose, and sulfolithocholylglycine were associated with both the PFAS mixture and T2D odds; the associations with sulfolithocholylglycine survived multiple testing corrections. Glutamate metabolism, arginine and proline metabolism, and drug metabolism-cytochrome p450 were the pathways associated with both the PFAS mixture and T2D.
"Findings may inform public health policy needed to reduce PFAS exposures in the environment, as well as precision-environmental health approaches for T2D prevention and treatment," the authors write.
One author served as an expert consultant for plaintiffs in litigation related to PFAS-contaminated drinking water; a second author disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
Rebound Weight Gain Common After Discontinuing Antiobesity Medications
FRIDAY, July 25, 2025 -- Antiobesity medications (AOMs) yield weight loss during use, followed by weight regain after discontinuation of treatment, according to a review published...
Patients Face High Out-of-Pocket Costs After Incident Cancer Diagnosis
FRIDAY, July 25, 2025 -- Patients face high out-of-pocket costs (OOPCs) after an incident diagnosis of cancer, with costs increasing with stage of diagnosis, according to a study...
More Than Half of Infants Diagnosed With HIV Did Not Receive Postnatal HIV Prophylaxis
THURSDAY, July 24, 2025 -- Although the rate of perinatal HIV infection is low, more than 50 percent of HIV infections in infants before age 1 year occurred in those who did not...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.